Explore the vast range of titles available.

Pharmacological probes are important tools for exploring disease biology and discovering new therapies. Often molecules of insufficient quality are used instead, leading to spurious and misleading results. The Boehringer Ingelheim open innovation portal opnMe.com addresses this deficiency by sharing extensively validated pharmacological probes with the scientific community.Pharmacological probes are important tools for exploring disease biology and discovering new therapies. Often molecules of insufficient quality are used instead, leading to spurious and misleading results. The Boehringer Ingelheim open innovation portal opnMe.com addresses this deficiency by sharing extensively validated pharmacological probes with the scientific community.

An individual's brain functional organization is unique and can reliably be observed using modalities such as functional magnetic resonance imaging (fMRI). Here we demonstrate that a quantification of the dynamics of functional connectivity (FC) as measured using electroencephalography (EEG) offers an alternative means of observing an individual's brain functional organization. Using data from both healthy individuals as well as from patients with Parkinson's disease (PD) ( n = 103 healthy individuals, n = 57 PD patients), we show that “dynamic FC” (DFC) profiles can be used to identify individuals in a large group. Furthermore, we show that DFC profiles predict gender and exhibit characteristics shared both among individuals as well as between both hemispheres. Furthermore, DFC profile characteristics are frequency band specific, indicating that they reflect distinct processes in the brain. Our empirically derived method of DFC demonstrates the potential of studying the dynamics of the functional organization of the brain using EEG.

Objective We aimed to determine whether the combination of two parameters: a) score of axial impairment and limb rigidity (SAILR) with b) EEG global relative median power in the frequency range theta 4-8 Hz (GRMPT) predicted cognitive outcome in patients with Parkinson’s disease (PD) better than each of these measures alone. Methods 47 non-demented patients with PD were examined and re-examined after 3 years. At both time-points, the patients underwent a comprehensive neuropsychological and neurological assessment and EEG in eyes-closed resting-state condition. The results of cognitive tests were normalized and individually summarized to obtain a “global cognitive score” (GCS). Change of GCS was used to represent cognitive changes over time. GRMPT and SAILR was used for further analysis. Linear regression models were calculated. Results GRMPT and SAILR independently predicted cognitive change. Combination of GRMPT and SAILR improved the significance of the regression model as compared to using each of these measures alone. GRMPT and SAILR only slightly correlate between each other. Conclusion The combination of axial signs and rigidity with quantitative EEG improves early identification of patients with PD prone to severe cognitive decline. GRMPT and SAILR seem to reflect different disease mechanisms. Significance Combination of EEG and axial motor impairment assessment may be a valuable marker in the cognitive prognosis of PD.

We investigated quantitative electroencephalography (qEEG) and clinical parameters as potential risk factors of severe cognitive decline in Parkinson's disease. We prospectively investigated 37 patients with Parkinson's disease at baseline and follow-up (after 3 years). Patients had no severe cognitive impairment at baseline. We used a summary score of cognitive tests as the outcome at follow-up. At baseline we assessed motor, cognitive, and psychiatric factors; qEEG variables [global relative median power (GRMP) spectra] were obtained by a fully automated processing of high-resolution EEG (256-channels). We used linear regression models with calculation of the explained variance to evaluate the relation of baseline parameters with cognitive deterioration. The following baseline parameters significantly predicted severe cognitive decline: GRMP theta (4-8 Hz), cognitive task performance in executive functions and working memory. Combination of neurocognitive tests and qEEG improves identification of patients with higher risk of cognitive decline in PD.

Background. Visuospatial dysfunction is among the first cognitive symptoms in Parkinson’s disease (PD) and is often predictive for PD-dementia. Furthermore, cognitive status in PD-patients correlates with quantitative EEG. This cross-sectional study aimed to investigate the correlation between EEG slowing and visuospatial ability in nondemented PD-patients. Methods. Fifty-seven nondemented PD-patients (17 females/40 males) were evaluated with a comprehensive neuropsychological test battery and a high-resolution 256-channel EEG was recorded. A median split was performed for each cognitive test dividing the patients sample into either a normal or lower performance group. The electrodes were split into five areas: frontal, central, temporal, parietal, and occipital. A linear mixed effects model (LME) was used for correlational analyses and to control for confounding factors. Results. Subsequently, for the lower performance, LME analysis showed a significant positive correlation between ROCF score and parietal alpha/theta ratio (b=.59, p=.012) and occipital alpha/theta ratio (b=0.50, p=.030). No correlations were found in the group of patients with normal visuospatial abilities. Conclusion. We conclude that a reduction of the parietal alpha/theta ratio is related to visuospatial impairments in PD-patients. These findings indicate that visuospatial impairment in PD-patients could be influenced by parietal dysfunction.

To find out which Quantitative EEG (QEEG) parameters could best distinguish patients with Parkinson's disease (PD) with and without Mild Cognitive Impairment from healthy individuals and to find an optimal method for feature selection. Certain QEEG parameters have been seen to be associated with dementia in Parkinson's and Alzheimer's disease. Studies have also shown some parameters to be dependent on the stage of the disease. We wanted to investigate the differences in high-resolution QEEG measures between groups of PD patients and healthy individuals, and come up with a small subset of features that could accurately distinguish between the two groups. High-resolution 256-channel EEG were recorded in 50 PD patients (age 68.8 ± 7.0 year; female/male 17/33) and 41 healthy controls (age 71.1 ± 7.7 year; female/male 20/22). Data was processed to calculate the relative power in alpha, theta, delta, beta frequency bands across the different regions of the brain. Median, peak frequencies were also obtained and alpha1/theta ratios were calculated. Machine learning methods were applied to the data and compared. Additionally, penalized Logistic regression using LASSO was applied to the data in R and a subset of best-performing features was obtained. Random Forest and LASSO were found to be optimal methods for feature selection. A group of six measures selected by LASSO was seen to have the most effect in differentiating healthy individuals from PD patients. The most important variables were the theta power in temporal left region and the alpha1/theta ratio in the central left region. The penalized regression method applied was helpful in selecting a small group of features from a dataset that had high multicollinearity.